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Abstract
Background and Purpose: Bladder radiotherapy is a management option for carefully selected patients with muscle-
invasive bladder cancer. However, the inability to visualize the tumor site during treatment and normal bladder movement
limits targeting accuracy and increases collateral radiation. A means to accurately and reliably target the bladder during
radiotherapy is needed.
Materials and Methods: Eighteen consecutive patients with muscle-invasive bladder cancer (T1–T4) elected bladder-
preserving treatment with maximal transurethral resection (TUR), radiation and concurrent chemotherapy. All underwent
endoscopic placement of 24-K gold fiducial markers modified with micro-tines (70 [2.960.9 mm.]; 19 [2.160.7 mm.) into
healthy submucosa 5-10 mm. from the resection margin, using custom-made coaxial needles. Marker migration was
assessed for with intra-op bladder-filling cystogram and measurement of distance between markers. Set-up error and
marker retention through completion of radiotherapy was confirmed by on-table portal imaging.
Results: Between 1/2007 and 7/2012, a total of 89 markers (3–5 per tumor site) were placed into 18 patients of mean age
73.6 years. Two patients elected cystectomy before starting treatment; 16/18 completed chemo-radiotherapy. All (100%)
markers were visible with all on-table (portal, cone-beam CT), fluoroscopy, plain-film, and CT-scan imaging. In two patients,
1 of 4 markers placed at the tumor site fell-out (voided) during the second half of radiotherapy. All other markers (80/82,
98%) were present through the end of radio-therapy. No intraoperative (e.g. uncontrolled bleeding, collateral injury) or
post-operative complications (e.g. stone formation, urinary tract infection, post-TUR hematuria .48 hours) occurred. Use of
micro-tined fiducial tumor-site markers afforded a 2 to 6-fold reduction in bladder-area targeted with high-dose radiation.
Discussion: Placement of the micro-tined fiducial markers into the bladder was feasible and associated with excellent
retention-rate and no complications. All markers were well-visualized during radiotherapy with all imaging modalities.
Bladder fiducial markers improve targeting accuracy, and may increase treatment efficacy and reduce morbidity from
collateral radiation.
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Introduction
Radical cystectomy with urinary diversion remains the gold-
standard treatment for localized muscle-invasive bladder cancer.
However, bladder preservation with tri-modality therapy (maxi-
mal transurethral resection, and combined chemo and radiother-
apy) remains an alternative for patients who have been thoroughly
counseled regarding the attendant risks and benefits of all
management options, including radical cystectomy [1]. Ideal
candidates for bladder sparing management should have low
stage, focal disease that is amenable to complete transurethral
tumor resection [2]. Despite the absence of direct randomized
trials comparing bladder preserving treatment and radical
cystectomy, tri-modality treatment with maximal transurethral
bladder tumor resection followed by different regimens of
combined radio and chemotherapy has, among patients with the
aforementioned disease features, achieved results comparable to
radical cystectomy in some trials [3].
Two key challenges to radiotherapy targeting accuracy and
precision are that the location of the bladder moves constantly,
and, that the tumor-site cannot be identified using CT-scan
imaging or on-table imaging. Consequently, the location of the
bladder tumor site during treatment cannot be predicted by the
planning-CT.
The need to improve the radio-therapeutic window is essential to
improve clinical outcomes using radiotherapy for bladder cancer.
The inability to localize the bladder walls at time of daily
treatment using current ‘‘on table’’ imaging modalities (e.g. portal
and cone-beam CT), results in: 1. Under-treatment because the entire
target (bladder), or a portion (bladder tumor site), are not treated
consistently throughout the (generally) 4–6 weeks of radiotherapy,
and 2. Over-treatment: delivery of radiation to collateral non-bladder
tissues, or, delivery of high-dose radiation to the bladder outside of
the tumor site target area.
Twenty-Four karat gold prostate fiducial markers (placed into
the apex and base of the prostate gland) have been shown to
significantly improve targeting and decrease collateral radiation
during radiotherapy for prostate cancer [4]. [5] The high
isodenisty of pure gold offers excellent visualization with portal
imaging. Given the inability to adequately target the tumor site for
bladder radiotherapy for muscle-invasive bladder cancer, we
sought to design fiducial markers and a placement protocol for use
to define the location of bladder tumor. Because prostate fiducial
markers have been shown to migrate [6] (decreases accuracy and
increases collateral radiation), we manufactured our markers with
micro-tines along their sides, to anchor each into place within the
submucosa. We sought to optimize our marker delivery protocol to
minimize risk for fall-out and migration. We also sought to test
whether the marker’s size (and thereby delivery-needle diameter/
gauge) could be reduced.
Beginning in January 2007, we designed a fiducial marker and
placement protocol to mark the tumor site in 15 consecutive
patients with localized muscle invasive ($T1NxM0) transitional
cell bladder cancer. Patients were thoroughly counseled regarding
the risks and benefits of all management options, including the
gold-standard– radical cystectomy and urinary diversion, in
addition to bladder preserving multi-modality treatment. All
markers were placed endoscopically into intact bladder submucosa
surrounding the tumor resection site.
The present work is a feasibility study, and describes our fiducial
marker design, placement technique, and outcomes of our early
experience.
Materials and Methods
Ethics statement
All patients gave written informed consent to undergo treatment
and participate in this study, and approval for this study was
obtained from our institution’s (University of California San
Francisco) Committee for Human Research.
Between January 2007 and July 2012, a total of 18 consecutive
patients with focal, T2, NX, M0 urothelial carcinoma, elected
bladder-preserving multi-modality treatment and underwent
endoscopic placement of fiducial markers into the bladder wall
(13 men and 5 women, mean age 73.7 and 73.4 years,
respectively). A total of 89 fiducial markers were placed into
healthy bladder submucosa ,0.5 cm. from the resection margin.
Fiducial markers and placement technique
All fiducial markers were 24-K gold (W.E. Mowrey, St. Paul,
MN.). Each was modified in our laboratory to have four
lengthwise rows of micro-tines, and was re-sterilized before
placement. (Figure 1) Each marker was delivered into healthy
bladder-submucosa (,5 mm from the tumor resection margin;
Figure 2) using custom-made 30 cm. 18G and 16G coaxial
needles (Popper & Sons, NY, USA) (Figure 1). A ‘‘plug’’ of
morcellized GelfoamTM was delivered with (behind) each marker,
so that it resided between the marker and the hole into the
submucosa created by the deployment needle. (Figure 3A). Care
was taken to advance the needle-tip obliquely beneath the bladder
mucosa only the minimal distance necessary to bury the open
needle-end within submucosa, before deploying the marker. A
total of 3 to 5 micro-tined fiducial markers were placed
circumferentially around each tumor resection site in a staggered
orientation, such that from all markers were visible from both
anterior-posterior and lateral radiographic views (Figure 3B). A single
surgeon (MMG) placed all of the markers. Diathermy was not
routinely used to control bleeding at the marker placement sites.
Fiducial marker placement at the bladder anatomic
margins
For the most recent 5 patients in our series, following marker
placement at the tumor resection site, fiducial markers were also
placed at the anatomic boundaries of the bladder (center posterior
wall, center of the left and right lateral-most point of the lateral
wall, and center dome), under combined direct and fluoroscopic
guidance.
Technique: A 16 Fr. urethral catheter was placed per urethra.
The bladder was filled with 60 ml. of diluted contrast/saline
solution, to allow visualization of the bladder lumen margins, a
cystoscope, delivery needle, and fiducial markers, under fluoros-
copy. Care was taken to ensure that the C-arm fluoroscope
remained fixed in place relative to the patient at all times. The
cystoscope was then inserted into the bladder, and under fluoroscopic
guidance, the tip was positioned at the desired anatomic margins
(lateral-most side wall, dome center, center posterior wall). A single
fiducial marker was deployed at each site under fluoroscopy.
For the first 12/18 patients in our series, all underwent intra-
operative Fluoroscopy and post-operative pelvis pelvic X-Ray
imaging to confirm placement and location of all markers.
(Figure 4)
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Assessment for intraoperative migration using filling
cystogram and a smartphone App
In the last 6 patients, to confirm that the markers tracked the
bladder wall throughout filling/emptying and did not migrate
intraoperatively, we also performed an intra-operative contrast
filling study under C-arm fluoroscopy. The C-arm was fixed in
place over the patient’s pelvis and the bladder was imaged empty
and then during filling and emptying (60 ml increments, from 0 to
240 ml., then 240 to 0 ml.). A spot fluoroscopic image was taken
after each 60 ml. change (+/2) in volume. This was performed
Figure 1. Gold bladder fiducial markers, GelfoamTM plug, and custom-made coaxial deployment needles. A. Each 24-K gold micro-
tined fiducial marker is manufactured with four length-wise rows of tines, whose points all face toward the center of the marker. The purpose of the
micro-tines is to prevent the marker from migrating within the submucosal space. Each marker is deployed via a custom-made 30-cm. coaxial 18G
needle into bladder submucosa. To prevent the marker from falling-out via the hole created by the placement needle, a small ‘‘plug’’ made of
morcellated GelfoamTM is deployed with (behind) the marker. B. 2.160.65 mm. gold fiducial markers are shown beside a custom-made 30-cm. coaxial
18G needle, and a U.S. dime.
doi:10.1371/journal.pone.0089754.g001
Figure 2. The tumor resection site is marked by a minimum of three fiducial markers placed circumferentially. Electrocautery will
cause necrosis of mucosa immediately adjacent to the resection site (purple). For this reason, we place the fiducial markers into healthy mucosa ,5–
10 mm lateral to the resection margin (‘‘X’’).
doi:10.1371/journal.pone.0089754.g002
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first with saline, followed by a repeat series using diluted contrast
(Figure 5). As both the patient’s pelvis and the C-arm remained
fixed in 3-dimensions throughout filling/emptying, any change in
the location of the fiducial markers could be detected and
measured. We now routinely fill the bladder with only 240 ml.
(saline and diluted contrast), as this lower volume is sufficient to
demonstrate marker tracking of the bladder wall.
For each bladder filing volume (i.e. 0R60R120R180R
240R240R180R120R60R0 ml.), we compared the location
of each marker in the contrast-filled versus saline-filled bladder
image (Figure 6 A, B).
We then used an image-based anatomic measurement smart-
phone App that we (MMG) designed (MedMeasure!, U.S. and
International Patents Pending, https://itunes.apple.com/us/app/
medmeasure!/id654898049?mt = 8) to measure the distance
(mm.) between matched pairs of fiducual markers at any given
equal volume of saline vs. contrast.
Technique: A photograph of the fluoroscopy image showing the
fiducial markers within the bladder was uploaded into the App. A
digital caliper was superimposed on the image within the App.
The caliper was calibrated to a known actual length (the actual
length of a lateral view of one of the fiducial markers; = 2.9 mm.).
(Figure 6C). Once calibrated, the caliper was re-positioned on the
image to measure actual (i.e. real) distance between matched
marker pairs. (Figure 6D, E)
Bladder tumor and fiducial marker mapping; post-op
management
We used a schematic bladder-map of the bladder to indicate
(intraoperatively) the tumor resection location in 3-dimensions, and,
the location of all fiducial markers (see Figure 5 & Video S1). We
also annotated any anatomic abnormalities (e.g. bladder divertic-
ulum, previous resection scars, ectopic ureteral orifice). Each
fiducial marker was numbered on this map and was referenced in
the operative report. The ‘‘bladder map’’ was then placed into each
patient’s electronic medical record, for easy reference by our
Radiation Oncology colleagues. All patients received an oral
prophylactic antibiotic for 5 days post-operatively. All patients were
contacted by telephone 24, 48, and 72 hours post-operatively for
follow-up assessment.
All patients who proceeded to radiotherapy underwent pre-
treatment computed tomography (CT) scan imaging for dosimetry
planning and portal imaging at time of daily radiotherapy
(Figure 7).
Figure 3. A. During placement, the tip of the deployment needle should be tunneled (approximately parallel to the bladder wall) a short distance
beneath the mucosa before the stylet is advanced to deploy the marker and GelfoamTM plug. Submucosal tissue collapses upon the micro-tines, to
anchor the fiducial marker in place and prevent marker migration. B. A minimum of three markers are placed around a single tumor site. Markers
should be oriented circumferentially in a trident (e.g. MercedesH-sign) rotated 30–60-degrees, such that when the three+ markers are viewed by
radiograph from either an anterior-posterior view and a lateral view, each is distinct and does not overlap with the others.
doi:10.1371/journal.pone.0089754.g003
Figure 4. Plain-film X-Ray images of the pelvis without (left) and
with (right) three 2.160.65 mm. 24K gold micro-tined fiducial
markers surrounding the resection site of a right posterior-lateral
bladder wall tumor.
doi:10.1371/journal.pone.0089754.g004
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Use of markers to assess potential on-table set-up/
targeting error during radiotherapy treatment visits
At treatment, patients were aligned ‘on-table’ with one of two
techniques: 1. Daily anterior-posterior (AP) and lateral-view portal
images were taken and the patient’s gold markers were aligned to
the gold markers on the reference digitally recreated radiograph,
or, 2. Daily MV cone-beam CT was performed and the patient
was aligned to the gold markers on the planning CT images.
To assess whether the presence of the markers improved
targeting, for the last 5 patients in our series, we measured set-up
error on the first 3 days of treatment as follows: patients were
aligned daily to skin marks using a 3-point set up. Portal images
were taken and overlaid with the planning Digitally Reconstructed
Radiograph (DRR). The position of the gold fiducial markers on
the planning CT and the daily on-table portal image were
compared. All patients were treated with IMRT using 6 MV
photons.
Results
A total of 89 markers were placed into 18 patients (Table 1). A
minimum of 3 to 4 ‘‘regular’’ size markers were used to mark the
tumor site. In the last 9/18 patients, a total of 21 ‘‘extra-small’’
(2.160.65 mm.) markers were also placed, each usually in
combination with a ‘‘regular’’ size (2.960.9 mm.) marker.
Occasionally more than 3 (up to 5) markers were placed at the
tumor site if it was felt that one or more of the first 3 markers was
at risk of falling-out prematurely- usually due to deployment too
close to the mucosa needle-entry hole.
In the last 5 patients in this series, 2–4 fiducial markers were also
placed at one or more bladder anatomic boundaries (center of
Figure 5. Intraoperatively, we completed a bladder map pictogram of the anterior and posterior walls of the bladder. On this bladder
map we drew the location of the bladder tumor, additional biopsy sites, and, abnormal anatomy (e.g. diverticulae, ectopic ureteral orifice, etc.), and,
the location of each fiducial marker placed (A.). We numbered each marker on the bladder map, and also referred to the numbered markers in the
dictated operative note. The bladder map was entered into each patient’s electronic medical record, for future reference by our Radiation Oncology
colleagues during dosimetry planning. Intraoperative fluoroscopic images of the catheterized bladder following placement of three fiduciary markers
at the site of a left anterior-lateral bladder wall tumor: (B.) Bladder empty. The location of the tumor and resection margin are outlined by three
fiducial markers; center is filled in color. The bladder was then filled with 300 cc. of saline (C.), and separately with diluted contrast (D.), to assess
marker movement with bladder filling and to compare the location of each marker during independent filling studies of equal volume.
doi:10.1371/journal.pone.0089754.g005
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lateral-most side walls, posterior wall and dome). In all (18/18)
patients, all markers (82/82; 100%) were clearly visible on intra-
operative fluoroscopy, and post-op pelvic X-ray (Figure 4).
Among patients who started radiotherapy, all (100%) markers
were visible on CT scan, and MV/cone-beam portal imaging
(Figure 7).
No (0%) intraoperative or post-operative complications oc-
curred. This includes hematuria beyond what can be expected
flooring transurethral tumor resection (.48 hours, hematuria
requiring transfusion or clot evacuation), UTI, injury to collateral
pelvic structures, development of bladder calculi, or chronic pain.
In our series, we used electrocautery to control mucosal bleeding
only once. We limited its use to avoid tissue necrosis and delayed
sloughing at the marker site – which would result in delayed
marker loss. In our experience, bleeding at the marker site is
generally minimal, and resolved spontaneously with the aid of a
urinary catheter left in place post-op and removed prior to same-
day discharge from hospital. Hematuria resolved within 24 hours
for the majority of patients, and within 48 hours post-operatively
for the remainder. At follow-up cystosopy, no patient demonstrat-
ed bladder calculi. For each of two patients, one marker fell-out
during placement (as a result of the placement needle not being
advanced sufficiently into the sub-mucosal space). In both
instances, the marker was retrieved with an endoscopic grasping
instrument, and immediately re-placed. To ensure that the open
portion of the beveled needle-tip is completely submucosal, we
found it most helpful to withdraw the needle very slightly- simply
to allow visualization of muscoa around the needle tip, before
advancing the stylet.
Two of 18 patients elected to undergo cystectomy before
initiating chemo-radiotherapy. The remaining 16 patients (82
markers) completed chemo-radiation therapy. In two patients
early in our series, two of the 4 markers placed fell out during the
last quarter of radiation therapy, resulting in a net marker-loss rate
of 2/82 markers = 2.4%. All other markers (80/82, 98%) were
Figure 6. In order to confirm that the fiducial markers move apart with bladder filling and move together with bladder emptying,
motion, immediately after all markers were placed, we performed a volumetric filling/emptying cystogram. Using diluted contrast, the
bladder was serially filled 0 ml to 240 ml. in 60 ml. increments, and then emptied from 240 ml. to 0 ml. also in 60 ml. increments, all while the patient
and fluoroscopy C-arm remained fixed in position. The same procedure was repeated, separately, with saline. At each incremental 60 ml. change in
bladder volume, we obtained a spot-fluoro image. We compared images of a patient’s bladder filled with equal volumes of dilute contrast (A) and
saline (B). We then used the digital image measurement App (MedMeasure!; U.S. and International Patents Pending) [https://itunes.apple.com/us/
app/medmeasure!/id654898049?mt= 8] to measure the distance between pairs of markers in paired images of the bladder filled with the same
volume of saline or contrast. The digital, scalable caliper provided by the MedMeasure! App is first calibrated to one of the fiducial markers visible in
lateral view– whose length of which is known to equal 2.9 mm. (C). Upon calibration, the actual distance between any two markers can be measured
with the caliper. We measured the difference in distance between each marker-pair in paired images. (D, E).
doi:10.1371/journal.pone.0089754.g006
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visible and remained in place through the end of radiation
therapy.
Assessment for intraoperative migration using filling
cystogram and a smartphone App
In all 5 patients evaluated, the markers appeared, grossly, to
remain in place during and after bladder filling with saline versus
diluted contrast. (See Video S1) The MedMeasure! App  was
used to calculate the mean change in location of each marker on
fluoroscopic images taken during bladder filling with equal
volumes of saline versus contrast, which was 2.32 mm. (range:
0.10–9.7 mm. (Figure 6) All 5 patients had at least one matched-
volume inter-marker distance measurement difference that was
,1 mm. and which occurred during the emptying phase of the
serial cystogram.
Use of markers to assess potential on-table set-up/
targeting error during radiotherapy treatment visits
During treatment of 5 patients, on each day of treatment, the
patient was initially aligned upon the table using only conventional
Figure 7. Computed Tomography (CT), Digitally Reconstructed Radiograph (DRR), and on-table Portal images with fiducial markers
present. (A.) Computed Tomography (CT-scan) dosimetry imaging of pelvis with bladder fiducial markers in place. The gross tumor volume (GTV;
dark blue) received 56-Gy in 25 fractions. The clinical tumor volume (CTV; light blue) equals the bladder and received 50 Gy in 25 fractions. The
planning tumor volume (PTV; purple) equals the CTV+1 cm + the ipsilateral pelvic side-wall. (B.) Digitally reconstructed radiograph (DRR) of pelvis;
shows the anticipated location of the three markers we placed at the tumor site (large black rectangles), based on the gold markers visible on
planning CT. (C.) Gold markers seen on an AP portal image of pelvis, (circled), (D) Fusion of the DRR and AP portal images showing the predicted
position for gold markers (red arrow) compared to the true position of the gold markers (green arrow) prior to any patient adjustment.
doi:10.1371/journal.pone.0089754.g007
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methods (skin tattoos, bony landmarks). Then, without the aid of
on-table spot-imaging, the Radiation Oncologist attempted to
predict the location of each of the gold fiducial markers within the
patient’s pelvis by consulting the archived dosimetry-planning non-
contrast CT scan images, which showed the fiducial markers. The
Radiation Oncologist then super-imposed dark-black rectangle
shapes upon the pelvis of the patient on the table – to mark where
he/she expected each marker to be (Figure 7, B). Next, on-table
imaging was performed which showed the actual location of the
markers (Figure 7, C). A Digitally Reconstructed Radiograph
(DRR) was made which showed the markers actual location within
the patient on-table, and their predicted location based on the
dosimetry-planning CT (black-shapes, Figure 7, D). The distance
between the expected vs. actual location of the fiducial markers
was measured in the X and Y dimensions. The discrepancy
between predicted versus actual location of the markers was
classified as ‘‘set up error’’. The average set up error in the X-
dimension was 1.96 cm. (range: 0.76–2.14), and in the Y-
dimension it was 0.95 cm. (range: 0.52–1.74)
Post-radiotherapy cystoscopy
All patients underwent cystoscopy approximately midway
through radiotherapy treatment and then every 3–6 months
following treatment. In all patients, the bladder mucosa covered
the fiducial markers (i.e. markers were not visible), and no patient
(0%) demonstrated bladder calculi.
Discussion
The bladder wall is a mobile structure and is not well-visualized
using on-table radiographic imaging available during radiothera-
py. An inability to visualize the exact location of the tumor
resection site precludes targeting it with high-dose radiation during
daily radiotherapy. We have shown that the novel gold fiducial
markers we describe can be easily delivered endoscopically into
bladder submucosa and appear to remain in place to identify the
tumor site and bladder-margins throughout radiotherapy. Our
intra-operative volumetric cystogram under fluoroscopy that the
distance between a matched-pair of markers varies generally little
(mean 2.32 mm.) but can vary up to ,1 cm. Because all patients
had at least 1 inter-marker distance measurement (after the
maximum discrepancy was detected) that was ,1 mm., it is
unlikely that the markers were actually migrating, but rather, that
the variance in inter-marker distance reflects changing position of
the bladder wall at the marker site(s).
In our experience, our markers improve on-table alignment
accuracy and precision. On table imaging throughout radiother-
apy showed that .98% of these fiducial markers are retained and
remain in place relative to one another and did not migrate.
Follow-up evaluations, including cystoscopy, confirm that the
patients in this series had no adverse sequelae that could be
attributed to the markers, such as bother, stone formation, or
infections.
Modern radiation-therapy techniques permit dose escalation to
the target without increasing the dose to the surrounding normal
tissues [7,8]. However, the location of the bladder on dosimetry-
planning CT-scan cannot accurately predict the exact location of
the bladder at treatment. The location of the bladder walls
changes constantly (changing urine volume, bowel activity, and
rectal distention [9,10]). Also, the tumor site cannot be identified
with CT-scan imaging, As a result, the field area (tumor site)
targeted for high-dose radiotherapy (HDR) (aka. Gross Tumor
Volume, GTV) during dosimetry planning is over-sized, which
increases collateral radiation with HDR [10–14]. Because the
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volume of a sphere is equal to 4/3p r3 ([15]), any increase in the
radius of the target area results in a large increase in the volume of
irradiated field. For example, conformal radiation of an actual
2 cm-wide tumor results in a HDR volume of 33.5 cm3, whereas if
the field area is increased to a 4 cm width, the irradiated HDR
volume is 268.1 cm3. Collateral radiation increases the incidence
of treatment morbidity: bladder/pelvic tissue ulceration, bleeding,
urinary frequency, urgency, and stone formation. [16,17]
Past efforts to account for bladder wall motion have not been
reliably successful. Use of external bony landmarks and skin
tattoos simply cannot improve targeting of the bladder wall. For
example, in our work, the mean discrepancy noted between the
location of the fiducial markers as visualized with on-table imaging
versus their predicted location based on the planning CT scan
DRR superimposed onto the on-table image was 1.96 cm. in the
X-dimension and 0.96 cm. in the Y-dimension. This measured
discrepancy reflects the fact that bladder motion can contribute
significantly to under-targeting of the tumor site and to collateral
radiation. It also suggests that the calculated set-up error likely
underestimates common set-up error to target the tumor site
because in this small experiment, the radiation oncologist was
allowed to use the location of the fiducial markers on the
dosimetry-planning CT to estimate their actual location within the
patient at moment of treatment. Without this aid, set-up error
could be greater.
Strategies to control bladder volume during radiotherapy (e.g.
drinking protocols [7,8,12,14]) and treatment verification proto-
cols using clips [18] have not been successful. Sondergaard et al.
report use of Lipiodol solution injected around the tumor site [19].
This technique has several limitations, which include dependence
on cone-beam CT imaging for visualization during intra-operative
injection at time of treatment, and, risk of solution migration
within or through the bladder (which when un-noticed, results in
over and/or under treatment). Ideally, the area of any fiducial
marker should not confound the targeting of the area it is supposed
to define. Hence, fiducial markers should ideally be ‘pin-point’ in
nature. Lastly, to be useful, markers must remain in place
throughout radiotherapy.
At our institution, owing to the uncertainty of tumor location
using on-table imaging and to anticipated bladder wall movement,
in order to minimize the risk of under-treating the tumor site with
HDR, approximately ,J of the total bladder area is targeted
with HDR. Because our fiducial markers allow us to identify the
tumor site independent of bladder motion using standard on-table
imaging, we were able to reduce the area of bladder targeted for
high-dose radiation by a factor of 2 to 6-fold.
We devised and began using our fiducial marker design, devices
and approach this before any published reports describing the use
of gold fiducial markers in the bladder. Mangar et al. published the
first report describing the use of gold fiducial markers placed
endoscopically into the bladder wall [20]. However, they did not
report any assessment to confirm that their markers actually
tracked the bladder wall during filling and emptying, and 25% of
their markers were lost before completion of radiotherapy. Our
marker design and approach is different in key respects. Ours have
a micro-tined surface and are significantly shorter in length (2–
3 mm vs. 10 mm used by Mangar). Our experience using the
smaller of the two fiducial marker sizes we used confirms that
markers as long as small as 2.1 mm by 0.65 mm can be seen in
plain radiograph films, dosimetry-planning CT, and during
treatment, on cone-beam CT and portal imaging. Mangar et al.
used gold fiducial markers that were significantly longer (8 and
10 mm.), which possibly contributed to their high immediate
marker fall-out rate (1 in 4).
Furthermore, in contrast to the flexible placement needle used
by Mangar et al, we used a rigid coaxial needle/stylet, which
affords complete control of the needle-tip depth of penetration. To
prevent immediate marker fall-out via the needle entry-hole in the
submucosa, we deliver a small amount of morcellized GelfoamTM
behind each marker. To further prevent marker fall-out and
migration, we tunnel our placement needle under the mucosa
before deploying the marker with the stylet, thus creating a ‘‘flap’’
of tissue which coapts around the marker and, with the help of the
micro-tines, helps to secure it in place. We strictly refrain from
routine use of diathermy at the placement site because the
resulting tissue necrosis will likely result in delayed marker fall-out.
We place markers only at the site of healthy/intact submucosa,
,5 mm. from the resection edge because tissue closer to the
resection-bed edge is will necrose and result in marker fall-out. We
use of custom-made long coaxial delivery needles because
cystoscopes are too long for use of long spinal needles or prostate
fiducial marker-placement needles.
A potential limitation of multi-modality therapy is that, ideally,
it should be practiced with close communication between the
urologist performing tumor resection/marker placement and the
treating radiation oncologist(s). Our fiducial marker protocol
speaks to this need: the intraoperative bladder-map informs the
radiation oncologist(s) about what was seen intraoperatively
(anatomic irregularities: e.g. bladder diverticulae, satellite and/or
irregularly shaped tumors), what tumor border each marker
identifies, and, the number and location of all markers. Also, if a
marker subsequently falls-out, it can be readily identified with this
bladder map. The images from the dilute-contrast filling study we
now routinely perform are regularly used by our radiation
oncology colleagues during dosimetry planning.
The present work serves principally to demonstrate the
feasibility and safety of our fiducial marker placement technique.
Future studies, with a greater number of patients and combined
with inter-fraction plain imaging, are needed to more rigorously
exclude marker migration. Future studies are also needed to assess
clinical outcomes among patients treated with bladder fiducial
markers (a report by our group on this is in progress). To formally
assess benefit regarding targeting accuracy and collateral radia-
tion, future studies should include an extra dosimetry-planning CT
scan and Dose Volume Histogram (DVH), made before marker
placement (i.e. blinded), so that this can be compared to the
dosimetry-planning CT after marker placement. Future work
should also explore the potential role of fiducial markers in
combination with newer treatment technologies, such as, for
example, Cyber Knife. Lastly, future work should report on
clinical outcomes among patients treated with fiducial-marker
targeted radiotherapy (work underway by our group), to poten-
tially further refine placement protocols and device design.
Supporting Information
Video S1 Three markers were placed to mark the
tumor site of a patient with unifocal T2 disease.
Immediately after placement, under Fluoroscopy, the empty
bladder was filled and then emptied (via a urethral catheter) with
dilute contrast in serial increments of 60 ml. (filling: 0 ml. to
240 ml, followed by emptying: 240 ml to 0 ml.) A Fluoroscopic
image of bladder was recorded at each volume. So that the
location of all markers could be easily compared relative to one
another and to bony landmarks, the position of the Fluoroscopy
unit and patient were fixed in space throughout imaging, so that
the only source of movement was the patient’s bladder and GI
motility. Comparisons of images of the fiducial markers within the
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bladder while the latter was filled with an equal volume of either
saline versus diluted contrast confirms that the markers move with
the bladder-wall as the bladder expands and contracts during
filling and emptying. Also, rapid serial images of the bladder were
captured while holding intravesical volume constant. These images
show how both the abdominal wall, intestines and the bladder-wall
move in 3D with visceral peristalsis and inspiration.
(MOV)
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